Pricing Log in Create free account

Capricor Therapeutics, Inc. (CAPR) vs Relmada Therapeutics, Inc. (RLMD)

Capricor Therapeutics, Inc. and Relmada Therapeutics, Inc. are both Biotechnology companies. Capricor Therapeutics, Inc. and Relmada Therapeutics, Inc. are of similar size ($479.1M and $455.5M). Across the 10 metrics below, Relmada Therapeutics, Inc. leads on 6 and Capricor Therapeutics, Inc. on 4.

Valuation

Metric CAPR RLMD Biotechnology median
P/E n/m n/m 10.64
P/S 21.17 n/m 9.59
P/B 1.92 2.32 2.15
Price to free cash flow 3.60 n/m 26.07
EV/EBITDA n/m n/m 0.65
EV/Sales 11.13 n/m 9.45
Earnings yield (30.10%) (22.37%) (34.69%)
Free cash flow yield 27.76% (26.54%) (24.02%)

Profitability

Metric CAPR RLMD Biotechnology median
Gross margin 100.00% 0.00% 65.59%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (73.70%) (55.66%) (51.96%)
Return on assets (51.53%) (51.57%) (46.06%)
Return on invested capital (1,019.73%) 0.00% 0.00%

Growth

Metric CAPR RLMD Biotechnology median
Revenue growth (TTM) (11.55%) — 4.59%
EPS growth (last fiscal year) (96.52%) 45.28% 29.88%
Revenue growth, 5-year CAGR 85.83% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CAPR RLMD Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.35 29.52 4.86
Net debt to EBITDA 2.99 1.57 1.01

Dividend

Metric CAPR RLMD Biotechnology median
Dividend yield — — 0.38%
Payout ratio — — —

Size

Metric CAPR RLMD Biotechnology median
Market cap 479.07m 455.48m 174.29m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack